Updated 6/16/2022. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
Results posted for 5 audits.
Manufacturer | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status | Manufacturer Contact Information |
---|---|---|---|---|---|---|
Akorn, Inc. | 17478 49411 50383 61748 |
IL |
|
Repayment to covered entities | CAP implemented Audit closure date: April 26, 2022 |
Chief Commercial Officer 847-582-6936 1925 West Field Court Suite 300 Lake Forest, IL 60045 Jon.Kafer@akorn.com |
BioComp Pharma | 44523 00178 |
TX | BioComp did not offer covered outpatient drugs to eligible covered entities at the statutory ceiling price. |
Repayment to covered entities | CAP approved | Compliance Coordinator – Medicaid 210-581-0683 10999 IH 10 West, Suite 1000 San Antonio, TX 78230 Iliana.herrera@missonpharmacal.com |
Chain Drug Marketing Association | 63868 | MI |
|
Repayment to covered entities | CAP approved | Medicaid Specialist 248-465-0670 W 9 Mile Road Novi, MI 48375 donnan@chaindrug.com |
Neos Therapeutics | 70165 62542 |
TX | No adverse findings | None | N/A |
|
TAGI Pharma, Inc. | 51224 68094 |
IL |
|
Repayment to covered entities | CAP implemented Audit closure date: May 20, 2022 |
TAGI Pharma, Inc.: Precision Dose, Inc.: |